+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Adalimumab"

From
From
Humira Drug Global Market Report 2024 - Product Thumbnail Image

Humira Drug Global Market Report 2024

  • Report
  • February 2024
  • 175 Pages
  • Global
From
Remicade Biosimilar Global Market Report 2024 - Product Thumbnail Image

Remicade Biosimilar Global Market Report 2024

  • Report
  • February 2024
  • 175 Pages
  • Global
From
TNF Alpha Inhibitors Global Market Report 2024 - Product Thumbnail Image

TNF Alpha Inhibitors Global Market Report 2024

  • Report
  • February 2024
  • 250 Pages
  • Global
From
Arthritis Monoclonal Antibodies Global Market Report 2024 - Product Thumbnail Image

Arthritis Monoclonal Antibodies Global Market Report 2024

  • Report
  • February 2024
  • 250 Pages
  • Global
From
Biosimilar Monoclonal Antibodies Global Market Report 2024 - Product Thumbnail Image

Biosimilar Monoclonal Antibodies Global Market Report 2024

  • Report
  • February 2024
  • 250 Pages
  • Global
From
Rheumatoid Arthritis Drugs Global Market Report 2024 - Product Thumbnail Image

Rheumatoid Arthritis Drugs Global Market Report 2024

  • Report
  • January 2024
  • 200 Pages
  • Global
From
From
From
Rheumatoid Arthritis - Pipeline Insight, 2024 - Product Thumbnail Image

Rheumatoid Arthritis - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 250 Pages
  • Global
From
Crohns Disease - Pipeline Insight, 2024 - Product Thumbnail Image

Crohns Disease - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 100 Pages
  • Global
From
Knee osteoarthritis - Pipeline Insight, 2024 - Product Thumbnail Image

Knee osteoarthritis - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
From
CTLA-4 inhibitors- Competitive landscape, 2023 - Product Thumbnail Image

CTLA-4 inhibitors- Competitive landscape, 2023

  • Report
  • May 2023
  • 220 Pages
  • Global
From
From
From
Loading Indicator

Adalimumab is a biologic drug used to treat a variety of immune disorders, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and juvenile idiopathic arthritis. It is a monoclonal antibody that works by blocking the action of tumor necrosis factor (TNF), a protein that plays a role in inflammation. Adalimumab is administered by subcutaneous injection and is available in both brand-name and generic forms. Adalimumab is one of the most widely prescribed drugs for immune disorders, and it has been approved for use in more than 100 countries. It is a highly effective treatment for many of the conditions it is used to treat, and it has been shown to improve quality of life for patients. Some of the companies in the Adalimumab market include AbbVie, Amgen, Biogen, Boehringer Ingelheim, Janssen Biotech, Merck, and Pfizer. Show Less Read more